Canaccord raised the firm’s price target on Prestige Consumer to $81 from $80 and keeps a Buy rating on the shares. The firm said they reported 1Q25 results coming in ahead of expectations, as management was able to keep the Clear Eyes brand well supplied at retail despite supply chain challenges.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- Prestige Consumer Healthcare Quarterly Financial Update
- Prestige Consumer sees FY25 adjusted EPS $4.40-$4.46, consensus $4.40
- Prestige Consumer reports Q1 adjusted EPS 90c, consensus 86c
- Is PBH a Buy, Before Earnings?
- Prestige Consumer Healthcare to Release Fiscal 2025 First Quarter Earnings Results